Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
86pct
166d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Medical Marijuana Research Act This bill establishes a new, separate registration process to facilitate medical marijuana research. Specifically, it directs the Drug Enforcement Administration to register (1) practitioners to conduct medical marijuana research, and (2) manufacturers and distributors to supply marijuana for such research. Additionally, the Department of Health and Human Services must continue to produce marijuana through the National Institute on Drug Abuse Drug Supply Program and implement a specialized process for supplying marijuana products available through state-authorized marijuana programs to researchers until manufacturers and distributors can provide a sufficient supply of marijuana for medical research.
Yes
343
No
75
Present
0
Not Voting
11
Party Breakdown
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (12)
Received in the Senate.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 343 - 75 (Roll no. 108). (text: CR H4136-4138)
HousePassed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 343 - 75 (Roll no. 108).(text: CR H4136-4138)
HouseConsidered as unfinished business. (consideration: CR H4144-4145)
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
DEBATE - The House proceeded with forty minutes of debate on H.R. 5657.
Considered under suspension of the rules. (consideration: CR H4136-4140)
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Bills with similar content found using semantic analysis.
Sources: Congress.gov · House Clerk roll-call votes
| house |
| On Motion to Suspend the Rules and Pass, as Amended |
Passed |
| April 4, 2022 |
2022 · fourth_quarter · Government Issues
As the federal government considers how to reconcile state legal cannabis programs with cannabis' federal illegality, the National Cannabis Roundtable supports legislation and regulatory paradigms that decriminalize cannabis, remediate the harm of the failed War on Drugs, ensure the highest standards of consumer safety, respect existing cannabis supply chains and provide equitable financial treatment for cannabis businesses. HR 1996, HR 3884 and HR 3105 are the three primary pieces of legislation which NCR has supported to achieve these goals. Additionally, NCR noted the introduction of HR 5977 by Congresswoman Mace and the HOPE Act by Reps. Ocasio-Cortez and Joyce during the fourth quarter of 2021 and looks forward to working with these congressional offices to advance areas of critical reform this year. NCR also discussed HOPE's inclusion in year end omni. NCR also supported the PREPARE Act (H.R. 7513) Finally, NCR supported the Medical Marijuana and Cannabidiol Research Act(signed into law)(HR 8454) and the Medical Marijuana Research Act (HR 5657).
Client expense: Not reported · Firm income: $65,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Government Issues
As the federal government considers how to reconcile state legal cannabis programs with the federal illegality of cannabis, NCR supported legislation and regulatory paradigms that decriminalize cannabis, remediate the harm of the failed War on Drugs, ensure the highest standards of consumer safety, respect existing cannabis supply chains and provide equitable financial treatment for cannabis businesses.HR 1996, HR 3884 and HR 3105 are the three primary pieces of legislation which NCR has supported to achieve these goals in the 117th Congress. NCR also discussed the potential of the HOPE Act being included in the end-of-year omnibus, which did not ultimately happen. NCR also noted the introduction of the PREPARE Act in the Senate (S.5166) and supported the Medical Marijuana and Cannabidiol Research Act(signed into law)(HR 8454) and the Medical Marijuana Research Act (HR 5657).
Client expense: Not reported · Firm income: $15,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Government Issues
HR 841 Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; all provisions of the bill HR 1996 SAFE Banking Act of 2021; all provisions of the bill HR 2617 Consolidated Appropriations Act, 2023; provisions related to establishing protections for depository institutions that provide financial services to cannabis-related legitimate businesses and service providers HR 3617 MORE Act of 2021; all provisions of the bill HR 4350 National Defense Authorization Act for Fiscal Year 2022; provisions related to SAFE banking HR 5657 Medical Marijuana Research Act; all provisions of the bill HR 5977 States Reform Act; all provisions of the bill S 253 Cannabidiol and Marihuana Research Expansion Act; all provisions of the bill S 4591 Cannabis Administration and Opportunity Act; all provisions of the bill Discussions in support of the establishment of a comprehensive federal regulatory framework for cannabis Discussions concerning federal appropriations policy related to Food and Drug Administration clarity on CBD
Client expense: $3,280,000 · Firm income: Not reported
2022 · fourth_quarter · Alcohol and Drug Abuse
S. 253 Cannabidiol and Marijuana Research H.R. 2067 Controlled Substances Act H.R. 2355 Informed Dispensing of Medications H.R. 2379 Grant Expansion of Opioid Use Disorders H.R. 5657 Accessible Marijuana Research H.R. 8454 Marijuana Impairment Research **Issued lobbied without specific bill number: Implementation of Marijuana Impairment Research
Client expense: Not reported · Firm income: $42,000
2022 · fourth_quarter · Alcohol and Drug Abuse
S. 253 Cannabidiol and Marijuana Research H.R. 2067 Controlled Substances Act H.R. 2355 Informed Dispensing of Medications H.R. 2379 Grant Expansion of Opioid Use Disorders H.R. 5657 Accessible Marijuana Research H.R. 8454 Marijuana Impairment Research **Issued lobbied without specific bill number: Implementation of Marijuana Impairment Research
Client expense: $1,420,000 · Firm income: Not reported
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsor introductory remarks on measure. (CR E1126)
Introduced in House
Congress.gov source codes: 1000, Intro-H
| Republican |
| OH |
| Debbie Dingell | Democratic | MI |
| Ed Case | Democratic | HI |
| Ed Perlmutter | Democratic | CO |
| Eleanor Holmes Norton | Democratic | DC |
| H. Morgan Griffith | Republican | VA |
| Nancy Mace | Republican | SC |
| Steve Cohen | Democratic | TN |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Transportation, Dept of (DOT)
2022 · fourth_quarter · Government Issues
As the federal government considers how to reconcile state legal cannabis programs with cannabis' federal illegality, CCIA supports legislation and regulatory paradigms that decriminalize cannabis, remediate the harm of the failed War on Drugs, ensure the highest standards of consumer safety, respect existing cannabis supply chains and provide equitable financial treatment for cannabis businesses. HR 1996, HR 3884 and HR 3105 are the three primary pieces of legislation which CCIA has supported to achieve these goals. Additionally, CCIA supported the SHIP Act HR 8825. To note, CCIA submitted comments to the discussion draft of the Cannabis Administration and Opportunity Act (CAOA) introduced by Senators Schumer, Booker and Wyden last year. CCIA supports the Senators' comprehensive approach to reform and looks forward to working with legislators on another version of the bill when it is formally introduced. Additionally, CCIA noted the introduction of HR 5977 by Congresswoman Mace and the Hope Act by Reps. Ocasio-Cortez and Joyce during the fourth quarter of 2021 and looks forward to working with these congressional offices to advance areas of critical reform this year. CCIA also supported the PREPARE Act (H.R. 7513). Finally, CCIA supports the Cannabidiol and Marijuana Research Expansion Act (S.253) and the Medical Marijuana Research Act (HR 5657).
Client expense: Not reported · Firm income: $8,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Government Issues
As the federal government considers how to reconcile state legal cannabis programs with cannabis' federal illegality, the National Cannabis Roundtable supports legislation and regulatory paradigms that decriminalize cannabis, remediate the harm of the failed War on Drugs, ensure the highest standards of consumer safety, respect existing cannabis supply chains and provide equitable financial treatment for cannabis businesses. HR 1996, HR 3884 and HR 3105 are the three primary pieces of legislation which NCR has supported to achieve these goals. Additionally, NCR noted the introduction of HR 5977 by Congresswoman Mace and the HOPE Act by Reps. Ocasio-Cortez and Joyce during the fourth quarter of 2021 and looks forward to working with these congressional offices to advance areas of critical reform this year. NCR also discussed HOPE's inclusion in year end omni. NCR also supported the PREPARE Act (H.R. 7513) Finally, NCR supported the Medical Marijuana and Cannabidiol Research Act(signed into law)(HR 8454) and the Medical Marijuana Research Act (HR 5657).
Client expense: Not reported · Firm income: $65,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities. H.R. 8585/S. 4851, the National Plan to End Parkinson's Act - to require the U.S. Department of Health and Human Services (HHS) to carry out a project to prevent and cure Parkinson's disease. Among other components of the project, HHS must (1) implement and periodically update a national plan to coordinate and guide efforts to prevent and cure the disease; (2) improve diagnosis, treatment, and care of those with the disease; and (3) address health and other disparities related to the disease. HHS must also conduct annual assessments on the preparation for and response to the increased burden of Parkinson's disease. In addition, the bill establishes a council, comprised of federal and nonfederal stakeholders, to advise HHS on and make recommendations concerning the prevention and cure of Parkinson's disease. Establishing Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and to allow researchers to gather more data to study the progression of Parkinson's among people living with the disease. Expanding access to health care for people living with Parkinson's via telehealth by removing Medicare telehealth geographic and originating site restrictions, extending coverage and reimbursement for health care providers who bill Medicare for providing services via telehealth (including seeing new patients and audio-only telehealth for clinically appropriate services/visits), ensuring payment parity for telehealth and in-person services, and removing Medicare in-person requirements for accessing mental health services via telehealth. H.R. 2617, the Consolidated Appropriations Act, 2023 Establishing separate Medicare payment requirements for diagnostic radiopharmaceuticals, including DaTscans, so health care providers are adequately reimbursed for furnishing diagnostic tests to help validate patients Parkinsons diagnoses. S. 2609/H.R. 4479, Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 S. 464/H.R. 2163, the Safe Step Act - to amend the Employee Retirement Income Security Act of 1974 (ERISA) to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol to enable people living with Parkinsons disease to access the medications they need to best manage their disease S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN (Bringing Regulatory Advances Into Neuroscience) Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT (Diverse and Equitable Participation in Clinical Trials) Act S. 331, ABLE (Achieving a Better Life Experience) Age Adjustment Act
Client expense: $20,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE
2022 · fourth_quarter · Health Issues
Cannabis legalization, regulation, and research, generally; S.253 - Cannabidiol and Marihuana Research Expansion Act; H.R.5657 - Medical Marijuana Research Act; S.4591 - Cannabis Administration and Opportunity Act, S.910 - SAFE Banking Act of 2021, H.R.1996 - SAFE Banking Act of 2021, H.R.3617 - Marijuana Opportunity Reinvestment and Expungement Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES
2022 · third_quarter · Alcohol and Drug Abuse
S. 253 Cannabidiol and Marihuana Research H.R. 2067 Controlled Substances Act H.R. 2355 Informed Dispensing of Medications H.R. 2379 Grant Expansion of Opioid Use Disorders H.R. 5657 Accessible Marijuana Research H.R. 8454 Marijuana Impairment Research
Client expense: Not reported · Firm income: $42,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Government Issues
HR 841 Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; all provisions of the bill HR 1996 SAFE Banking Act of 2021; all provisions of the bill HR 3617 MORE Act of 2021; all provisions of the bill HR 4350 National Defense Authorization Act for Fiscal Year 2022; provisions related to SAFE banking HR 5657 Medical Marijuana Research Act; all provisions of the bill HR 5977 States Reform Act; all provisions of the bill S 253 Cannabidiol and Marihuana Research Expansion Act; all provisions of the bill S 4591 Cannabis Administration and Opportunity Act; all provisions of the bill Discussions in support of the establishment of a comprehensive federal regulatory framework for cannabis Discussions concerning federal appropriations policy related to Food and Drug Administration clarity on CBD
Client expense: $3,220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Alcohol and Drug Abuse
S. 253 Cannabidiol and Marihuana Research H.R. 2067 Controlled Substances Act H.R. 2355 Informed Dispensing of Medications H.R. 2379 Grant Expansion of Opioid Use Disorders H.R. 5657 Accessible Marijuana Research H.R. 8454 Marijuana Impairment Research
Client expense: $1,380,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Cannabis legalization, regulation, and research, generally; S.253 - Cannabidiol and Marihuana Research Expansion Act; H.R.5657 - Medical Marijuana Research Act; S.4591 - Cannabis Administration and Opportunity Act, S.910 - SAFE Banking Act of 2021, H.R.1996 - SAFE Banking Act of 2021, H.R.3617 - Marijuana Opportunity Reinvestment and Expungement Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Government Issues
As the federal government considers how to reconcile state legal cannabis programs with cannabis' federal illegality, the National Cannabis Roundtable supports legislation and regulatory paradigms that decriminalize cannabis, remediate the harm of the failed War on Drugs, ensure the highest standards of consumer safety, respect existing cannabis supply chains and provide equitable financial treatment for cannabis businesses. HR 1996, HR 3884 and HR 3105 are the three primary pieces of legislation which NCR has supported to achieve these goals. To note, NCR submitted comments to the discussion draft of the Cannabis Administration and Opportunity Act (CAOA S4591) introduced by Senators Schumer, Booker and Wyden last year. NCR supports the Senators' comprehensive approach to reform and looks forward to working with legislators on another version of the bill when it is formally introduced. Additionally, NCR noted the introduction of HR 5977 by Congresswoman Mace and the Hope Act by Reps. Ocasio-Cortez and Joyce during the fourth quarter of 2021 and looks forward to working with these congressional offices to advance areas of critical reform this year. NCR also supported the PREPARE Act (H.R. 7513) Finally, NCR supports the Cannabidiol and Marihuana Research Expansion Act (S.253) and the Medical Marijuana Research Act (HR 5657).
Client expense: Not reported · Firm income: $65,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Government Issues
As the federal government considers how to reconcile state legal cannabis programs with cannabis' federal illegality, CCIA supports legislation and regulatory paradigms that decriminalize cannabis, remediate the harm of the failed War on Drugs, ensure the highest standards of consumer safety, respect existing cannabis supply chains and provide equitable financial treatment for cannabis businesses. HR 1996, HR 3884 and HR 3105 are the three primary pieces of legislation which CCIA has supported to achieve these goals. Additionally, CCIA supported the SHIP Act HR 8825. To note, CCIA submitted comments to the discussion draft of the Cannabis Administration and Opportunity Act (CAOA) introduced by Senators Schumer, Booker and Wyden last year. CCIA supports the Senators' comprehensive approach to reform and looks forward to working with legislators on another version of the bill when it is formally introduced. Additionally, CCIA noted the introduction of HR 5977 by Congresswoman Mace and the Hope Act by Reps. Ocasio-Cortez and Joyce during the fourth quarter of 2021 and looks forward to working with these congressional offices to advance areas of critical reform this year. CCIA also supported the PREPARE Act (H.R. 7513). Finally, CCIA supports the Cannabidiol and Marijuana Research Expansion Act (S.253) and the Medical Marijuana Research Act (HR 5657).
Client expense: Not reported · Firm income: $8,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth S.4906 Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253/H.R.8454, the Cannabidiol and Marihuana Research Expansion Act/ Medical Marijuana and Cannabidiol Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577, A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331, ABLE Age Adjustment Act H.R. 5376, the Inflation Reduction Act of 2022 H.R. 8585/S. 4851, the National Plan to End Parkinson's Act
Client expense: $31,190 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE
2022 · second_quarter · Alcohol and Drug Abuse
S. 253 Cannabidiol and Marihuana Research H.R. 2067 Controlled Substances Act H.R. 2355 Informed Dispensing of Medications H.R. 2379 Grant Expansion of Opioid Use Disorders H.R. 5657 Accessible Marijuana Research
Client expense: $1,620,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Government Issues
HR 841 Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; all provisions of the bill HR 1996 SAFE Banking Act of 2021; all provisions of the bill HR 3617 MORE Act of 2021; all provisions of the bill HR 4350 National Defense Authorization Act for Fiscal Year 2022; provisions related to SAFE banking HR 5657 Medical Marijuana Research Act; all provisions of the bill HR 5977 States Reform Act; all provisions of the bill S 253 Cannabidiol and Marihuana Research Expansion Act; all provisions of the bill Discussions in support of the establishment of a comprehensive federal regulatory framework for cannabis Discussions concerning federal appropriations policy related to Food and Drug Administration clarity on CBD
Client expense: $3,020,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Alcohol and Drug Abuse
S. 253 Cannabidiol and Marihuana Research H.R. 2067 Controlled Substances Act H.R. 2355 Informed Dispensing of Medications H.R. 2379 Grant Expansion of Opioid Use Disorders H.R. 5657 Accessible Marijuana Research
Client expense: Not reported · Firm income: $42,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Medical/Disease Research/Clinical Labs
H.R. 5657: Medical Marijuana Research ActSupport S. 253: Cannabidiol and Marihuana Research Expansion ActSupport
Client expense: $490,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Law Enforcement/Crime/Criminal Justice
H.R. 1621: Prohibiting Punishment of Acquitted Conduct ActSupport H.R. 1693: EQUAL ActSupport H.R. 1924: Kenneth P. Thompson Begin Again ActSupport H.R. 2453: Driving for Opportunity ActSupport H.R. 2489: Martha Wright Prison Phone Justice ActSupport H.R. 2588: Veterans Medical Marijuana Safe Harbor ActSupport H.R. 2738: Fourth Amendment Is Not For Sale ActSupport H.R. 2830: GRAM ActSupport H.R. 2864: Clean Slate Act of 2021Support H.R. 5977: States Reform ActSupport H.R. 6129: Harnessing Opportunities by Pursuing Expungement Act of 2021Support S. 1183: Veterans Medical Marijuana Safe Harbor Act.Support S. 1541: Martha Wright-Reed Just and Reasonable Communications Act of 2021Support S. 2502: Kenneth P. Thompson Begin Again ActSupport S. 253: Cannabidiol and Marihuana Research Expansion ActSupport S. 601: Prohibiting Punishment of Acquitted Conduct ActSupport S. 79: EQUAL ActSupport S. 998: Driving for Opportunity ActSupport H.R. 5657: Medical Marijuana Research ActSupport
Client expense: $490,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Medical/Disease Research/Clinical Labs
Issues relating to cannabis research, including the DEA Aug. 12 2016 solicitation of applications to manufacture cannabis for research purposes (Docket No. DEA-447) S. 253 - Cannabidiol and Marihuana Research Expansion Act H.R. 5657 - Medical Marijuana Research Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · second_quarter · Health Issues
Cannabis legalization, regulation, and research, generally; S.253 - Cannabidiol and Marihuana Research Expansion Act; H.R.5657 - Medical Marijuana Research Act; H.R.3617 - Marijuana Opportunity Reinvestment and Expungement Act (MORE) Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Government Issues
As the federal government considers how to reconcile state legal cannabis programs with cannabis' federal illegality, the National Cannabis Roundtable supports legislation and regulatory paradigms that decriminalize cannabis, remediate the harm of the failed War on Drugs, ensure the highest standards of consumer safety, respect existing cannabis supply chains and provide equitable financial treatment for cannabis businesses. HR 1996, HR 3884 and HR 3105 are the three primary pieces of legislation which NCR has supported to achieve these goals. To note, NCR submitted comments to the discussion draft of the Cannabis Administration and Opportunity Act (CAOA) introduced by Senators Schumer, Booker and Wyden last year. NCR supports the Senators' comprehensive approach to reform and looks forward to working with legislators on another version of the bill when it is formally introduced. Additionally, NCR noted the introduction of HR 5977 by Congresswoman Mace and the Hope Act by Reps. Ocasio-Cortez and Joyce during the fourth quarter of 2021 and looks forward to working with these congressional offices to advance areas of critical reform this year. NCR also supported the PREPARE Act (H.R. 7513) Finally, NCR supports the Cannabidiol and Marihuana Research Expansion Act (S.253) and the Medical Marijuana Research Act (HR 5657).
Client expense: Not reported · Firm income: $65,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Government Issues
As the federal government considers how to reconcile state legal cannabis programs with cannabis' federal illegality, CCIA supports legislation and regulatory paradigms that decriminalize cannabis, remediate the harm of the failed War on Drugs, ensure the highest standards of consumer safety, respect existing cannabis supply chains and provide equitable financial treatment for cannabis businesses. HR 1996, HR 3884 and HR 3105 are the three primary pieces of legislation which CCIA has supported to achieve these goals. To note, CCIA submitted comments to the discussion draft of the Cannabis Administration and Opportunity Act (CAOA) introduced by Senators Schumer, Booker and Wyden last year. CCIA supports the Senators' comprehensive approach to reform and looks forward to working with legislators on another version of the bill when it is formally introduced. Additionally, CCIA noted the introduction of HR 5977 by Congresswoman Mace and the Hope Act by Reps. Ocasio-Cortez and Joyce during the fourth quarter of 2021 and looks forward to working with these congressional offices to advance areas of critical reform this year. CCIA also supported the PREPARE Act (H.R. 7513). Finally, CCIA supports the Cannabidiol and Marijuana Research Expansion Act (S.253) and the Medical Marijuana Research Act (HR 5657).
Client expense: Not reported · Firm income: $8,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2023, Provisions relating to NIH, Substance Use Research Barriers to research resulting from DEA scheduling, Drug research related issues S.253, Cannabidiol & Marijuana Research Expansion Act, Drug use research related issues H.R.5657, Medical Marijuana Research Act, Drug use research related issues H.R.869/S.289, Research Investment to Spark the Economy Act of 2021 (RISE ACT), Drug use research related issues H.R.1910, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.2366, Support, Treatment and Overdose Prevention of Fentanyl Act H.R.2405, Streamlining Research on Controlled Substances Act H.R.2430, To amend the Temporary Reauthorization and Study of Emergency Scheduling of Fentanyl Analogues Act to extend for one year the temporary order for fentanyl-related substances S.339, Federal Initiative to Guarantee Health by Targeting Fentanyl Act S.1006, Amend Controlled Substances Act to list fentanyl-related substances to Schedule I controlled substances Public Law 117-70, Extending Temporary Emergency Scheduling of Fentanyl Analogues Act, Drug use research related issues Cannabis Administration and Opportunity Act, Drug use research H.R.6184/S.3336, HALT Fentanyl Act, Drug use research related issues H.R.6946, SAFE Act of 2022, Drug use research related issues
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2022 · second_quarter · Medical/Disease Research/Clinical Labs
Education and training for health practitioners who deliver medications and treatment for individuals with Substance Abuse Disorders (SUDs) H.R.1384/S.445, Mainstreaming Addiction Treatment Act H.R. 2067, Medication Access and Training Expansion Act H.R.6279/S.3629, Opioid Treatment Access Act H.R.7666, Restoring Hope for Mental Health and Well-Being Act of 2022, Entirety S.253, Cannabidiol & Marijuana Research Expansion Act, Cannabis research related issues H.R.5657, Medical Marijuana Research Act, Cannabis research related issues
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
-Reconciliation legislation, support additional funding for Medicaid home- and community-based services; addressing affordability of health insurance premiums; creating an out-of-pocket cap in Medicare Part D with smoothing mechanism; bar use of discriminatory quality-adjusted life year (QALY) in prescription drug legislation; preserving the Orphan Drug Tax Credit; expand Medicaid. -S. 3799 PREVENT Pandemics Act, incorporate disability into pandemic preparedness legislation Work has stalled on this, we had success in committee but havent done much on it since we could take it out -S. 464/H.R. 2163, Safe Step Act, support passage. -S. 253, Marihuana Research Expansion Act and H.R. 5657, Medical Marijuana Research Act, support passage. -Identify and make recommendations on improvements to federal law for access to medical cannabis and medical cannabis products. -H.R. 5435, BRAIN Act, S. 3427, Neuroscience Center of Excellence Act and H.R. 6000, Cures 2.0 Act, support creation of a Neuroscience Center of Excellence at the FDA that is patient-focused and related necessary appropriations. - S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 / H.R. 7667 Food and Drug Amendments Act of 2022, ensure that any new regulation of dietary supplements protects access to CBD, support amendment to ban use of certain electric shock devices, support provisions regarding diverse enrollment in clinical trials, support provisions to support orphan drug development
Client expense: $65,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · second_quarter · Health Issues
General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month" S. 331: ABLE Age Adjustment Act
Client expense: $61,153 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE
2022 · first_quarter · Alcohol and Drug Abuse
S. 253 Cannabidiol and Marihuana Research H.R. 2067 Controlled Substances Act H.R. 2355 Informed Dispensing of Medications H.R. 2379 Grant Expansion of Opioid Use Disorders H.R. 5657 Accessible Marijuana Research
Client expense: $1,370,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Government Issues
HR 841 Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act of 2021; all provisions of the bill HR 1996 SAFE Banking Act of 2021; all provisions of the bill HR 3617 MORE Act of 2021; all provisions of the bill HR 5657 Medical Marijuana Research Act; all provisions of the bill HR 5977 States Reform Act; all provisions of the bill S 253 Cannabidiol and Marihuana Research Expansion Act; all provisions of the bill Discussions in support of the establishment of a comprehensive federal regulatory framework for cannabis
Client expense: $2,980,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
-Build Back Better Act or similar legislation, support $400 billion for Medicaid home- and community-based services; addressing affordability of health insurance premiums; creating an out-of-pocket cap in Medicare Part D with smoothing mechanism; bar use of discriminatory quality-adjusted life year (QALY) in prescription drug legislation; preserving the Orphan Drug Tax Credit; creating a comprehensive paid family and medical leave program; add vision, dental, and hearing coverage to Medicare; expand Medicaid. -S. 3799 PREVENT Pandemics Act, incorporate disability into pandemic preparedness legislation. -S. 464/H.R. 2163, Safe Step Act, support passage. -S. 253, Marihuana Research Expansion Act and H.R. 5657, Medical Marijuana Research Act, support passage. -Identify and make recommendations on improvements to federal law for access to medical cannabis and medical cannabis products. -H.R. 5435, BRAIN Act, S. 3427, Neuroscience Center of Excellence Act and H.R. 6000, Cures 2.0 Act, support creation of a Neuroscience Center of Excellence at the FDA that is patient-focused and related necessary appropriations.
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · first_quarter · Alcohol and Drug Abuse
S. 253 Cannabidiol and Marihuana Research H.R. 2067 Controlled Substances Act H.R. 2355 Informed Dispensing of Medications H.R. 2379 Grant Expansion of Opioid Use Disorders H.R. 5657 Accessible Marijuana Research
Client expense: Not reported · Firm income: $42,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
Cannabis legalization, regulation, and research, generally; S.253 - Cannabidiol and Marihuana Research Expansion Act; H.R.5657 - Medical Marijuana Research Act; H.R.3617 - Marijuana Opportunity Reinvestment and Expungement Act (MORE) Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
H.R.4502, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2022, Provisions relating to NIH, substance use research Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2023 Public Law 117-103, Consolidated Appropriations Act, FY2022 Public Law 117-86, Further Additional Extending Government Funding Act Barriers to research resulting from DEA scheduling, Drug research related issues S.253, Cannabidiol & Marijuana Research Expansion Act, Drug use research related issues H.R.5657, Medical Marijuana Research Act, Drug use research related issues H.R.869/S.289, Research Investment to Spark the Economy Act of 2021 (RISE ACT), Drug use research related issues H.R.1910, Federal Initiative to Guarantee Health by Targeting Fentanyl Act H.R.2366, Support, Treatment and Overdose Prevention of Fentanyl Act H.R.2405, Streamlining Research on Controlled Substances Act H.R.2430, To amend the Temporary Reauthorization and Study of Emergency Scheduling of Fentanyl Analogues Act to extend for one year the temporary order for fentanyl-related substances S.339, Federal Initiative to Guarantee Health by Targeting Fentanyl Act S.1006, Amend Controlled Substances Act to list fentanyl-related substances to Schedule I controlled substances Public Law 117-70, Extending Temporary Emergency Scheduling of Fentanyl Analogues Act, Drug use research related issues Cannabis Administration and Opportunity Act, Drug use research H.R.6184/S.3336, HALT Fentanyl Act, Drug use research related issues
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2022 · first_quarter · Government Issues
As the federal government considers how to reconcile state legal cannabis programs with cannabis' federal illegality, the National Cannabis Roundtable supports legislation and regulatory paradigms that decriminalize cannabis, remediate the harm of the failed War on Drugs, ensure the highest standards of consumer safety, respect existing cannabis supply chains and provide equitable financial treatment for cannabis businesses. HR 1996, HR 3884 and HR 3105 are the three primary pieces of legislation which NCR has supported to achieve these goals. To note, NCR submitted comments to the discussion draft of the Cannabis Administration and Opportunity Act (CAOA) introduced by Senators Schumer, Booker and Wyden last year. NCR supports the Senators' comprehensive approach to reform and looks forward to working with legislators on another version of the bill when it is formally introduced. Additionally, NCR noted the introduction of HR 5977 by Congresswoman Mace and the Hope Act by Reps. Ocasio-Cortez and Joyce during the fourth quarter of 2021 and looks forward to working with these congressional offices to advance areas of critical reform this year. Finally, NCR supports the Cannabidiol and Marihuana Research Expansion Act (S.253) and the Medical Marijuana Research Act (HR 5657).
Client expense: Not reported · Firm income: $65,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression Advocating for expanding access to care via telehealth Advocating for rulemaking to ensure standards in the Americans with Disabilities Act (ADA) are applied to the internet Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS) S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act S. 253, the Cannabidiol and Marihuana Research Expansion Act S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act H.R. 5657, the Medical Marijuana Research Act H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021 H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act S. 1670/H.R. 3321, the Credit for Caring Act H.R. 253, the Adult Day Care Center Enhancement Act S. 464/H.R. 2163, the Safe Step Act H.R. 3013, the COVID Vaccine Transportation Access Act H.R. 2503, the Social Determinants Accelerator Act of 2021 H.R. 6000, the Cures 2.0 Act H.R. 4521, the America COMPETES Act of 2022 H.R. 2565/S. 2952, the FDA Modernization Act of 2021 H.R. 5435 BRAIN Act of 2021 S. 3427, the Neuroscience Center of Excellence Act of 2021 H.R. 6584, the DEPICT Act S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month"
Client expense: $57,949 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE
2021 · fourth_quarter · Alcohol and Drug Abuse
S. 253 Cannabidiol and Marihuana Research H.R. 2067 Controlled Substances Act H.R. 2355 Informed Dispensing of Medications H.R. 2379 Grant Expansion of Opioid Use Disorders H.R. 5657 Accessible Marijuana Research
Client expense: Not reported · Firm income: $42,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Health Issues
S. 289/ H.R. 869: Research Investment to Spark the Economy Act of 2021 S. 610/ H.R. 1667: Lorna Breen Health Care Provider Protection Act S. 834/ H.R. 2256: Resident Physician Shortage Reduction Act S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021 S. 1024/H.R. 2255: Healthcare Workforce Resilience Act S. 1548/H.R. 3085: Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S. 1810/H.R. 3541: Conrad State 30 and Physician Access Reauthorization Act H.R. 2754: COVID-19 Long Haulers Act H.R. 4122: Resident Education Deferred Interest Act of 2021 H.R. 5435: Bringing Regulatory Advances into Neuroscience (BRAIN) Act S.1692/H.R.3354: Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act H.R. 5376: Build Back Better Act; sections 139001-139003, 139101, 139102, 139201, 139202, 31060, 137402, 137405, 30601, 30602, 137301, and 30801 H.R. 5657: Medical Marijuana Research Act Supporting vaccine requirements for health care workers. Urging reforms to proposed surprise billing regulations to align with congressional intent for payment disputes. Support for creating a Neuroscience Center of Excellence at FDA. Support for eliminating the prohibition on national unique patient identifier. Supporting policies to address the COVID-19 public health emergency, including maintaining telemedicine coverage and ensuring access to affordable health coverage and medications. Support for funding the CDC National Neurological Conditions Surveillance System. Medical research funding related to fetal tissue, AHRQ, Congressionally Directed Medical Research Programs at the Department of Defense, and the NIH including the BRAIN Initiative. Support for funding for the Pediatric Subspecialty Loan Repayment Program.
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · fourth_quarter · Alcohol and Drug Abuse
S. 253 Cannabidiol and Marihuana Research H.R. 2067 Controlled Substances Act H.R. 2355 Informed Dispensing of Medications H.R. 2379 Grant Expansion of Opioid Use Disorders H.R. 5657 Accessible Marijuana Research
Client expense: $1,340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Aviation Administration (FAA), Federal Bureau of Investigation (FBI), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), Transportation, Dept of (DOT), Treasury, Dept of, White House Office
2021 · fourth_quarter · Health Issues
-Build Back Better Act, support $400 billion for Medicaid home- and community-based services; addressing affordability of health insurance premiums; creating an out-of-pocket cap in Medicare Part D with smoothing mechanism; bar use of discriminatory quality-adjusted life year (QALY) in prescription drug legislation; preserving the Orphan Drug Tax Credit; creating a comprehensive paid family and medical leave program; add vision, dental, and hearing coverage to Medicare; expand Medicaid. -Ensure access to medications in emergencies in pandemic preparedness legislation. -S. 464/H.R. 2163, Safe Step Act, support passage. -S. 253, Marihuana Research Expansion Act and HR 5657 Medical Marijuana Research Act, support passage. -Identify and make recommendations on improvements to federal law for access to medical cannabis and medical cannabis products. -H.R. 5435, BRAIN Act, support passage and creation of a Neuroscience Center of Excellence at the FDA.
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · fourth_quarter · Alcohol and Drug Abuse
S. 253 Cannabidiol and Marihuana Research H.R. 2067 Controlled Substances Act H.R. 2355 Informed Dispensing of Medications H.R. 2379 Grant Expansion of Opioid Use Disorders H.R. 5657 Accessible Marijuana Research
Client expense: Not reported · Firm income: $42,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Health Issues
General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities Advocating for Parkinson's patients during COVID-19 including extension of health care subsidies Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely S.253 the Cannabidiol and Marihuana Research Expansion Act S.1467/H.R.2916 the VA Medicinal Cannabis Research Act H.R.5657 The Medical Marijuana Research Act S.1670/H.R.3321 the Credit for Caring Act S.464/H.R.2163 Safe Step Act H.R.3013 COVID Vaccine Transportation Access Act H.R.2503 Social Determinants Accelerator Act of 2021 H.R.6000 Cures 2.0
Client expense: $49,562 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA)